Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

Teva Pharmaceutical Industries Ltd. ADR-1.50% $19.99B ...

Copyright © 2025 MarketWatch, Inc. All rights reserved.

Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90. The company’s shares opened today at p1,443. ...

The Food and Drug Administration on Friday gave a green light to a new meningococcal vaccine from GSK. Dubbed Penmenvy, the “5-in-1” shot is approved for people aged 10 through 25 years old and ...

NEW YORK, NY / ACCESS Newswire / February 18, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

The Food and Drug Administration (FDA) announced that Penmenvy will be allowed for use in individuals aged 10-to-25 years old following two successful Phase III trials. GSK said safety data from ...

Vaccine makers face a demand cliff as coronavirus vaccines wane, but these stocks are more than meets the eye.